A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)

• Status: Completed
• Trial end date: 2009-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the bioequivalence of single oral doses of aprepitant (MK0869) to a single intravenous infusion of fosaprepitant (MK0517) and also determine the effect of food on the bioavailability of oral aprepitant.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Aprepitant; Fosaprepitant

Criteria

Inclusion Criteria:

• Subject is in good health

• Subject is a nonsmoker

• Subject is willing to comply with the study restrictions

Exclusion Criteria:

• Subject has a history of any illness that might confound the results of the study or might make participation in the study unsafe

• Subject has a history of stroke, seizures, or major neurological disorder

• Subject has a history of cancer

• Subject consumes more than two alcoholic drinks per day

• Subject consumes more than three caffeinated beverages daily